JOHN KIRKWOOD to Combined Modality Therapy
This is a "connection" page, showing publications JOHN KIRKWOOD has written about Combined Modality Therapy.
Connection Strength
1.345
-
Plain language summary of the CheckMate 76K study results: nivolumab given after stage 2B/2C?melanoma is removed by surgery. Future Oncol. 2024 May; 20(15):959-968.
Score: 0.173
-
Multiple antigen-engineered DC vaccines with or without IFNa to promote antitumor immunity in melanoma. J Immunother Cancer. 2019 04 24; 7(1):113.
Score: 0.124
-
Adjuvant Therapy in Resected Melanoma. N Engl J Med. 2018 02 15; 378(7):679-680.
Score: 0.114
-
Avoiding Severe Toxicity From Combined BRAF Inhibitor and Radiation Treatment: Consensus Guidelines from the Eastern Cooperative Oncology Group (ECOG). Int J Radiat Oncol Biol Phys. 2016 06 01; 95(2):632-46.
Score: 0.101
-
Adjuvant Therapy of Melanoma. Cancer Treat Res. 2016; 167:181-208.
Score: 0.099
-
Neoadjuvant therapy for high-risk bulky regional melanoma. J Surg Oncol. 2011 Sep; 104(4):386-90.
Score: 0.073
-
Mature results of a phase III randomized trial of bacillus Calmette-Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer Stage I-III melanoma (E1673): a trial of the Eastern Oncology Group. Cancer. 2004 Apr 15; 100(8):1692-8.
Score: 0.044
-
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716 trial. J Immunother Cancer. 2024 Mar 13; 12(3).
Score: 0.043
-
Medical management of melanoma. Surg Clin North Am. 2003 Apr; 83(2):283-322, viii.
Score: 0.041
-
Adjuvant high-dose interferon-alpha therapy for high-risk melanoma. Forum (Genova). 2003; 13(2):127-40; quiz 187-8.
Score: 0.040
-
Update on adjuvant interferon therapy for high-risk melanoma. Oncology (Williston Park). 2002 Sep; 16(9):1177-87; discussion 1190-2, 1197.
Score: 0.039
-
High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: results of the Multicenter Eastern Cooperative Oncology Group Phase II Trial E2696. J Clin Oncol. 2001 Mar 01; 19(5):1430-6.
Score: 0.035
-
CTLA-4 blockade and interferon-a induce proinflammatory transcriptional changes in the tumor immune landscape that correlate with pathologic response in melanoma. PLoS One. 2021; 16(1):e0245287.
Score: 0.035
-
Dysregulated NF-?B-Dependent ICOSL Expression in Human Dendritic Cell Vaccines Impairs T-cell Responses in Patients with Melanoma. Cancer Immunol Res. 2020 12; 8(12):1554-1567.
Score: 0.034
-
Update on the role of adjuvant interferon for high risk melanoma. Forum (Genova). 2000 Jul-Sep; 10(3):230-9.
Score: 0.034
-
Granulocyte-macrophage colony-stimulating factor: another cytokine with adjuvant therapeutic benefit in melanoma? J Clin Oncol. 2000 Apr; 18(8):1603-5.
Score: 0.033
-
CD56dim CD16- Natural Killer Cell Profiling in Melanoma Patients Receiving a Cancer Vaccine and Interferon-a. Front Immunol. 2019; 10:14.
Score: 0.031
-
Systemic adjuvant treatment of high-risk melanoma: the role of interferon alfa-2b and other immunotherapies. Eur J Cancer. 1998 Jul; 34 Suppl 3:S12-7.
Score: 0.029
-
Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy. Cell. 2017 Sep 07; 170(6):1109-1119.e10.
Score: 0.028
-
Immune Correlates of GM-CSF and Melanoma Peptide Vaccination in a Randomized Trial for the Adjuvant Therapy of Resected High-Risk Melanoma (E4697). Clin Cancer Res. 2017 Sep 01; 23(17):5034-5043.
Score: 0.027
-
Interferon adjuvant therapy of melanoma. Cancer. 1997 May 01; 79(9):1843-6.
Score: 0.027
-
The adjuvant treatment of malignant melanoma. J Fla Med Assoc. 1997 Mar; 84(3):147-52.
Score: 0.027
-
Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol. 1996 Jan; 14(1):7-17.
Score: 0.025
-
Hyperthermic isolated limb perfusion with tumor necrosis factor alone for melanoma. Cancer J Sci Am. 1995 Nov-Dec; 1(4):274-80.
Score: 0.024
-
Studies of interferons in the therapy of melanoma. Semin Oncol. 1991 Oct; 18(5 Suppl 7):83-90.
Score: 0.018
-
Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma. J Clin Oncol. 2008 May 10; 26(14):2292-8.
Score: 0.015
-
Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol. 2006 Oct 10; 24(29):4738-45.
Score: 0.013
-
Combined chemoradiotherapy vs. radiotherapy alone for early stage squamous cell carcinoma of the esophagus: a study of the Eastern Cooperative Oncology Group. Int J Radiat Oncol Biol Phys. 1998 Sep 01; 42(2):269-76.
Score: 0.007
-
Phase I/II study of murine monoclonal antibody-ricin A chain (XOMAZYME-Mel) immunoconjugate plus cyclosporine A in patients with metastatic melanoma. J Immunother Emphasis Tumor Immunol. 1993 Apr; 13(3):201-7.
Score: 0.005
-
Estrogen receptor concentration and social factors as predictors of natural killer cell activity in early-stage breast cancer patients. Confirmation of a model. Nat Immun Cell Growth Regul. 1990; 9(5):313-24.
Score: 0.004
-
Glioblastoma multiforme: pathology, natural history and treatment. Cancer Treat Rev. 1984 Mar; 11(1):1-26.
Score: 0.003